Canakinumab as New Approach in Heart Attack Fight also Tackles Cancer

Published Date : Aug 28, 2017

Canakinumab, hailed as a larger breakthrough since the advent of statins, has been prognosticated to be a new sensation amongst the drugs used to prevent scores of heart attacks and cancer casualties. According to modern-day scientists, this drug has set the scene for a new era of therapeutics that has been operating in a completely different manner than traditional treatments. It has been studied to shield against arthritis and gout and half the possibility of becoming extinct due to cancer, besides abating the risk of heart attack by a quarter.

Canakinumab has been stated by Harvard Medical School’s Professor Paul Ridker to have uncovered a third front in the fight against heart disease. Ridker had showcased his findings yesterday in Barcelona at a European Society of Cardiology conference. The four-year landmark study has tracked a 10,000 heart attack patients and involved a 1,000 doctors in 39 countries. The drug has worked wonders by attaining a 17.0% decline in angina and reducing heart attacks by a 24.0%.

Canakinumab Attacks Interleukin-1, which Causes Increased Inflammation

The trial has been anticipated to be a definitive evidence of heart attack risk being slashed with the cutting down of inflammation. Cholesterol-busting statins have been the go-to treatment for the last 30 years in a bid to protect against strokes and heart attacks. However, nearly 50.0% of the 200,000 heart attack patients recorded in Britain each year do not suffer from high cholesterol. This has conveyed the need to take a different route in the prevention or treatment of cardiovascular diseases. The study authors have said they have discovered for the first time that cardiovascular risk could be reduced by lowering inflammation independent of cholesterol.